Individualized Weight Loss
*Based on Ivim’s published study, Ivim patients following the Ivim Protocol lost an average of 46% more weight over 68 weeks when compared to another published clinical GLP-1 trial that included a daily 500-calorie deficit, 150 minutes of weekly exercise, and in-person counseling every four weeks. Not a head-to-head study. RX required after clinical evaluation. This is a compounded medication and is not FDA-approved. Compounded drugs have not undergone FDA review for safety, efficacy, or quality. See Ivím website for full safety information. Results may vary.
Your Ivím GLP-1 ID Patient Journey
Here’s how it works:
What your individual program includes
Competitors
Medicine
ONLY
$850 value
coaching & community
$500 value
formulated supplements
Ivím Health App
What to Expect
Your Ivím GLP-1 ID Patient Journey
Understanding individualized compounded GLP-1 medications
Learn more about GLP-1s
-
Travel Constipation Is Real. A Doctor Explains How to Prevent It.
Constipation during travel is widely reported and thinly studied, and an obesity medicine physician says most of what causes it is set in motion before the traveler leaves the house. “We hear about this all the time […]
-
July Webinar Recap: Understanding the Connection Between GLP-1s and Your Hormones
If you’ve started a GLP-1 medication and noticed changes beyond the number on the scale, you’re not imagining it. Maybe your appetite has changed (of course), but so has your energy. Your menstrual cycle feels different. Your mood is shifting. You’re wondering whether your hair shedding […]
-
42% of Women in Their Early 40s Aren’t Sure If They’re in Perimenopause. So They’re Getting Answers Online.
By Kara Fellows for Ivím Health More than 34% of women don’t know what reproductive stage they’re in according to a new study published in The Menopause Society’s journal Menopause. That confusion peaks in a key group. […]
*Based on Ivim’s published study, Ivim patients following the Ivim Protocol lost an average of 46% more weight over 68 weeks when compared to another published clinical GLP-1 trial that included a daily 500-calorie deficit, 150 minutes of weekly exercise, and in-person counseling every four weeks. Not a head-to-head study. RX required after clinical evaluation. This is a compounded medication and is not FDA-approved. Compounded drugs have not undergone FDA review for safety, efficacy, or quality. See Ivím website for full safety information. Results may vary.
*Based on our internal data and individual patient outcomes may vary. This does not constitute a guarantee of specific results.
✝ These results include data from patients using both FDA-approved and compounded formulations.
Individualized virtual integrative medicine (IVIM): A clinical model for enhanced GLP-1 therapeutic outcomes



